Comparison of two rescue therapy protocols for treating patients with PONV after outpatient cancer surgery under general anesthesia

Presenter: Hanae Tokita, MD

### Background

- Incidence of postoperative nausea and vomiting (PONV) is 30% in the general population.<sup>1</sup>
- PONV is associated with longer post anesthesia care unit (PACU) stays, unanticipated hospital admission, increased costs, and significant patient distress.<sup>2-3</sup>
- Limited evidence on optimal combination rescue therapy for PONV.
- New institution-wide PONV rescue protocol at Memorial Sloan Kettering Cancer Center (MSK) implemented in 2022 to be in line with recent guidelines.
- Aim: to investigate PONV-related outcomes after outpatient cancer surgery at MSK's Josie Robertson Surgery Center (JRSC).

### Methods

- IRB-approved retrospective study
- Before change (10/1/2017-5/31/2022): N=11,641
- After change (8/1/2022-4/14/2023): N=1,877
- Multivariable logistic regression to test the association between protocol period and PONVrelated outcomes (need for second line antiemetic and prolonged stay) adjusting for: age, preoperative Apfel score, ASA score, surgical service, operative time, gas vs total intravenous anesthesia (TIVA), total intraoperative opioids (MMEs), intraoperative midazolam, and preoperative and intraoperative antiemetics.

#### Discussion

- Updated protocol, with amisulpride as first-line rescue antiemetic, was not associated with clinically meaningful changes to probability of PONV-related outcomes.
- Might be due to already low rates of PONV outcomes after outpatient surgery at JRSC
- Current pathway remains the standard of care.

Updated protocol: **amisulpride**, as a first-line rescue antiemetic, was **not associated** with clinically meaningful **changes** to **probability** of **PONV**-related outcomes.




Figure 1. PONV rescue therapy protocol at JRSC before and after June 2022

**Table 1.** Patient characteristics by study period. Estimates are presented as n (%) and median (quartile 1, quartile 3). P-values were generated by Wilcoxon rank sum test and Pearson's Chi-squared test.

Characteristic	<b>Before</b> , N = 11,641	<b>After</b> , $N = 1,877$	p-value	
Age	55 (46, 65)	57 (47, 66)	< 0.001	
ASA Score 3-4	30 (0.3%)	3 (0.2%)	0.6	
Unknown	2	0		
Apfel Score 3-4	2,781 (24%)	382 (20%)	<0.001	
BMI	27 (23, 32)	27 (24, 32)	0.090	
Female	10,432 (90%)	1,633 (87%)	<0.001	
Anesthetic Type			<0.001	
Gas	5,448 (47%)	1,293 (69%)		
TIVA	6,193 (53%)	584 (31%)		
Hispanic	972 (8.8%)	177 (10%)	0.039	
Unknown	624	175		
Race			<0.001	
Asian	795 (6.8%)	141 (7.5%)		
Black	1,063 (9.1%)	176 (9.4%)		
Other	451 (3.9%)	79 (4.2%)		
Unknown	437 (3.8%)	111 (5.9%)		
White	8,895 (76%)	1,370 (73%)		
Service			<0.001	
BRE	2,221 (19%)	418 (22%)		
GMT	411 (3.5%)	81 (4.3%)		
GYN	1,850 (16%)	320 (17%)		
HNS	855 (7.3%)	145 (7.7%)		
PLA	5,891 (51%)	804 (43%)		
URO	413 (3.5%)	109 (5.8%)		

Characteristic	<b>Before</b> , N = 11,641	<b>After</b> , $N = 1,877$	p-value	
Operative Time (mins)	64 (41, 95)	64 (41, 95)	0.6	
Preoperative PONV Medications Administered			0.7	
0	8,888 (76%)	1,450 (77%)		
1	2,725 (23%)	423 (23%)		
2	28 (0.2%)	4 (0.2%)		
Intraoperative Midazolam	10,033 (86%)	1,543 (82%)	<0.001	
Intraoperative PONV Medications Administered			<0.001	
0	142 (1.2%)	19 (1.0%)		
1	1,196 (10%)	138 (7.4%)		
2	10,292 (88%)	1,717 (91%)		
3	11 (<0.1%)	3 (0.2%)		
Intraoperative Opioids (MMEs)	20 (20, 40)	20 (15, 30)	<0.001	
Unknown	110	34		

### Results

Characteristic	<b>1</b> , N = 1,214	<b>2</b> , N = 281	<b>3</b> , N = 46	<b>4</b> , N = 12	<b>5</b> , N = 3
PONV Medication					
Ondansetron	1,150 (95%)	42 (15%)	12 (26%)	9 (75%)	3 (100%)
Metoclopramide	23 (1.9%)	137 (49%)	10 (22%)	0 (0%)	0 (0%)
Compazine	22 (1.8%)	80 (28%)	8 (17%)	0 (0%)	0 (0%)
Lorazepam	8 (0.7%)	15 (5.3%)	5 (11%)	3 (25%)	0 (0%)
Benedryl	8 (0.7%)	7 (2.5%)	8 (17%)	0 (0%)	0 (0%)
Scopolamine	1 (<0.1%)	0 (0%)	2 (4.3%)	0 (0%)	0 (0%)
Amisulpride	0 (0%)	0 (0%)	1 (2.2%)	0 (0%)	0 (0%)
Aprepitant	1 (<0.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Promethazine	1 (<0.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

After							
Characteristic	<b>1</b> , N = 210	<b>2</b> , N = 49	<b>3</b> , N = 15	4, N = 4	<b>5</b> , N = 2	<b>6</b> , N = 1	7, N = 1
PONV Medication							
Amisulpride	188 (90%)	2 (4.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ondansetron	17 (8.1%)	30 (61%)	4 (27%)	3 (75%)	0 (0%)	1 (100%)	1 (100%)
Benedryl	2 (1.0%)	12 (24%)	4 (27%)	1 (25%)	0 (0%)	0 (0%)	0 (0%)
Lorazepam	0 (0%)	2 (4.1%)	4 (27%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)
Metoclopramide	2 (1.0%)	2 (4.1%)	2 (13%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Compazine	1 (0.5%)	1 (2.0%)	1 (6.7%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)

**Table 1.** Type of postoperative antiemetic use by study period where columns represent the rescue antiemetic sequence (i.e., first-line, second-line rescue).

# No statistically significant change in **need for second-line antiemetic:**

- Before change: 281 (2.4%)
- After change: 49 (2.6%)
- No evidence of a statistically or clinically significant difference associated with being treated in the after period, 0.10% (95% CI -0.18%, 0.37%; p=0.5)

## No statistically significant change in rate of extended stays (6+ hours) due to PONV:

- Before change: 1.0% (118)After change: 1.2% (22)
- Adjusted absolute increase in risk negligible, 0.07% (95% CI 0.09%, 0.23%; p=0.3)

#### References

- Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. Aug 2020;131(2):411-448. doi:10.1213/ANE.0000000000000004833
  Habib AS, Chen YT, Taguchi A, Hu XH, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. Curr Med Res Opin. Jun 2006;22(6):1093-9. doi:10.1185/030079906X104830
- 3. Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery--a prospective study. Can J Anaesth. Jul 1998;45(7):612-9. doi:10.1007/BF03012088

### Authors

Kristie Kim<sup>1</sup>; Melissa Assel, MS<sup>2</sup>; Joanna Serafin, PhD<sup>2</sup>; Kara Barnett, MD<sup>3</sup>; **Hanae Tokita, MD<sup>2</sup>** 

<sup>1</sup>University of Central Florida College of Medicine, <sup>2</sup>Josie Robertson Surgery Center, Memorial Sloan Kettering Cancer Center <sup>3</sup>Memorial Sloan Kettering Cancer Center Monmouth

### Acknowledgements

This research was funded through the FAER Medical Student Anesthesia Research Fellowship and NIH/NCI Grant under award number 5R25CA020449.



